An SCD patient in Bahrain received the gene-editing therapy Casgevy, marking the first time the treatment has been given outside the U.S.

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.

Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US MANAMA, Kingdom of Bahrain, Feb ...

The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY’s use in the NHS. It means that eligible SCD ...

HRH Prince Salman highlighted the Kingdom’s medical milestone in successfully completing the treatment of the world’s first sickle cell disease patient outside the US with Casgevy (exagamglogene ...

His Royal Highness Prince Salman bin Hamad Al Khalifa, the Crown Prince and Prime Minister, reaffirmed Bahrain’s commitment ...

Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...